MAY 0 2 2000



PATENT No.: 19226/931 (R-5495)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

icant(s): David G. Hangauer, Jr., Thomas H. Marsilje, and Karen L. Milkidwicz

Serial No. : 09/482,585

Filed

: January 13, 2000

For

: A NOVEL METHOD FOR DESIGNING PROTEIN KINASE INHIBITORS

TRANSMITTAL LETTER

Assistant Commissioner For Patents Washington, D.C. 20231

Box: Missing Parts

Dear Sir:

In response to the Notice to File Missing Parts of Application Under 37 CFR 1.53(d), which was mailed by the United States Patent and Trademark Office on **March 30, 2000**, enclosed are:

- [X] A Combined Declaration and Power of Attorney.
- A Request for (One, Two or Three)-Month Extension of Time.
- [X] A verified statement to establish small entity status under 37 CFR 1.9 and 1.27.
- [X] A Request for Corrected Filing Receipt and Copy of Official Filing Receipt.
- [X] A copy of the Notice to File Missing Parts.
- [X] A self-addressed, prepaid postcard for acknowledging receipt.
- [X] Fees as calculated below:

FEE FOR (ONE, TWO OR THREE)-MONTH EXTENSION OF TIME \$

SURCHARGE 37 CFR 1.16(e)

\$65.00

ADDITIONAL FEES

\$

TOTAL FEES SUBMITTED HEREWITH

\$65.00

- [X] A check in the amount of \$65.00 to cover the above fees.
- [X] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 14-1138. A duplicate copy of this sheet is enclosed.

Date: 4/24/00

Dennis M. Connolly Registration No. 40,964

Nixon Peabody LLP Clinton Square, P.O. Box 1051 Rochester, New York 14603 Telephone: (716) 263-1741 Facsimile: (716) 263-1600 Certificate of Mailing - 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date below.

Pate Ruth R. Smith

R394327.1



PATENT 19226/931 (R-5495)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Hangauer et al.) Examiner:) Unknown
Serial No	:	09/482,585) Art Unit:
Filed	:	January 13, 2000) 1643
For	:	A NOVEL METHOD FOR DESIGNING PROTEIN KINASE INHIBITORS)))

REQUEST FOR CORRECTED FILING RECEIPT

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, D.C. 20231

Dear Sir:

Applicants hereby request a corrected filing receipt for the aboveidentified application. On the enclosed copy of the official filing receipt, the entity status is omitted. It should read "SMALL ENTITY", per the small entity declaration being filed with the enclosed Response to Notice to File Missing Parts.

Since Applicants are not responsible for this error, no fee is enclosed.

Respectfully submitted,

Dated: $\frac{\sqrt{/\zeta y}}{}$, 2000

Dennis M. Connolly Registration No. 40,96

Nixon Peabody LLP Clinton Square, P.O. Box 31051 Rochester, New York 14603-1051

Telephone: (716) 263-1741 Facsimile: (716) 263-1600

Certificate of Mailing - 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the

Data

Ruth R. Smith





UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: ASSISTANT SECRETARY AND COMMISSIONER OF PATENT AND TRADEMARKS Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/482,585	01/13/2000	1643	938	19226/931 (R-5495)	15	69	6

Michael L. Goldman Nixon Peabody LLP Clinton Square P. O. Box 1051 Rochester, NY 14603



Date Mailed: 03/30/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

David G. Hangauer JR., East Amherst, NY; Thomas H. Marsilje, Buffalo, NY; Karen L. Milkiewicz, Buffalo, NY;

Continuing Data as Claimed by Applicant

THIS APPLN CLAIMS BENEFIT OF 60/115.643 01/13/1999

Foreign Applications

If Required, Foreign Filing License Granted 03/07/2000

" SMALLENTITY

Title

Novel method for designing protein kinase inhibitors

Preliminary Class

435



Data entry by: RIVERS, ANNETTE

Team: OIPE

Date: 03/30/2000

MAY 0 2 2000 W

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENT AND TRADEMARKS Washington, D.C. 20231

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/482,585

01/13/2000

David G. Hangauer JR.

19226/931 (R-5495)

Michael L. Goldman Nixon Peabody LLP Clinton Square P. O. Box 1051 Rochester, NY 14603



Date Mailed: 03/30/2000

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given TWO MONTHS from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- Total additional claim fee(s) for this application is \$882.
- \$882 for 49 total claims over 20.
- · The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- The balance due by applicant is \$ 998.

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

05/05/2000 MMARMOL 00000085 09482585

01 FC:205

65.00 OP